Erasca, Inc. (ERAS)

NASDAQ: ERAS · IEX Real-Time Price · USD
9.77
+1.30 (15.35%)
Aug 12, 2022 4:00 PM EDT - Market closed
15.35%
Market Cap 1.34B
Revenue (ttm) n/a
Net Income (ttm) -141.21M
Shares Out 137.11M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 498,848
Open 8.81
Previous Close 8.47
Day's Range 8.61 - 10.05
52-Week Range 4.51 - 24.47
Beta n/a
Analysts Buy
Price Target 22.95 (+134.9%)
Earnings Date Aug 25, 2022

About ERAS

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients... [Read more...]

Industry Biotechnology
IPO Date Jul 16, 2021
Employees 123
Stock Exchange NASDAQ
Ticker Symbol ERAS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ERAS stock is "Buy." The 12-month stock price forecast is 22.95, which is an increase of 134.90% from the latest price.

Price Target
$22.95
(134.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Erasca Reports Second Quarter 2022 Financial Results and Business Updates

Initial Phase 1b monotherapy data for ERAS-007 in HERKULES-1 and first-in-human Phase 1 monotherapy data for ERAS-601 in FLAGSHP-1 expected in H2 2022

Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 244%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 244% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the posi...

Wall Street Analysts See a 288% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High?

The consensus price target hints at a 288% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat...

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 an...

ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial

Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 362%: Here's is How to Trade

The consensus price target hints at a 361.8% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim...

Erasca to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Proof-of-concept data from trial may support addition of ERAS-007 as a treatment option to overcome RAS/MAPK resistance to KRAS G12C inhibitors Proof-of-concept data from trial may support addition of E...

Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments

Shannon Morris, M.D., Ph.D., appointed as Senior Vice President of Clinical Development

Erasca, Inc. (ERAS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Erasca, Inc. (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revi...

Erasca Reports First Quarter 2022 Financial Results and Business Updates

Presented compelling preclinical data at 2022 AACR Annual Meeting supporting clinical development of potentially best-in-class programs

Erasca to Present at the Bank of America Securities 2022 Healthcare Conference

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pati...

Erasca Appoints Jean Liu to its Board of Directors

Ms. Liu, currently chief legal officer at Seagen, brings decades of business and legal experience and will also join Erasca's audit committee Ms. Liu, currently chief legal officer at Seagen, brings dec...

Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERA...

ERAS-007 is a potent and selective small molecule ERK1/2 inhibitor with long target residence time, which promotes sustained RAS/MAPK pathway inhibition

Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the...

Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center

Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates

Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi)

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 an...

ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant mCRC

Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting

Posters will feature programs with best-in-class potential including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and CNS-penetrant KRAS G12C inhibitor ERAS-3490 Posters will feature programs wit...

Is a Surprise Coming for Erasca (ERAS) This Earnings Season?

Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day

SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

Erasca Strengthens Leadership Team with Two Key Executive Appointments

Lisa Tesvich-Bonora appointed as Chief People Officer

Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR...

IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in  recurrent GBM anticipated in Q1 2022

Erasca Added to the Nasdaq Biotechnology Index

SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

Erasca Reports Third Quarter 2021 Financial Results and Business Updates

Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i)

Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity aga...

ERAS-801's CNS penetration: four times higher than approved EGFR inhibitors Comprehensive inhibition against oncogenic EGFR vIII and wildtype alterations Improved outcomes in over 90% of EGFR-driven pat...